#1 Clinical Trials Search in Europe

Co-Trimoxazole

This article examines the use of Co-Trimoxazole, a combination antibiotic, in several clinical trials targeting different medical conditions. Co-Trimoxazole, composed of trimethoprim and sulfamethoxazole, has been studied for its effectiveness in treating various infections and its potential preventive properties. The trials discussed here investigate its use in tuberculosis, melioidosis, pneumocystis pneumonia, COVID-19, undifferentiated febrile illness, neonatal infections, and spontaneous bacterial peritonitis in cirrhosis patients.

Table of Contents

What is Co-trimoxazole?

Co-trimoxazole is an antibiotic medication used to treat various bacterial infections. It is also known by other names such as trimethoprim-sulfamethoxazole (TMP-SMZ), Bactrim, or Septra[1][2]. Co-trimoxazole is a combination of two antibiotics: trimethoprim and sulfamethoxazole, usually in a 1:5 ratio[3].

Uses of Co-trimoxazole

Co-trimoxazole is used to treat various infections, including:

  • Tuberculosis: It is being studied as a potential treatment for multidrug-resistant or extensively drug-resistant tuberculosis (MDR/XDR-TB)[1].
  • Melioidosis: A bacterial infection common in tropical regions[2].
  • Pneumocystis Pneumonia (PCP): A type of pneumonia that often affects people with weakened immune systems, such as those with HIV[3].
  • Prosthetic Joint Infections: Infections that can occur after joint replacement surgery[4].
  • Undifferentiated Febrile Illness: Fever without a clear cause, often seen in regions where diseases like typhoid fever are common[5].
  • Neonatal Infections: Infections in newborn babies[6].
  • Spontaneous Bacterial Peritonitis: An infection of the abdominal cavity lining, often occurring in people with liver cirrhosis[7].

How Co-trimoxazole Works

Co-trimoxazole works by stopping the growth of bacteria. It does this by interfering with the bacteria’s ability to produce folic acid, which is essential for their survival. This antibiotic has a broad spectrum of activity, meaning it can fight against many different types of bacteria[1].

In addition to its antibacterial properties, some research suggests that co-trimoxazole may have anti-inflammatory and immunomodulatory effects. This means it might help regulate the body’s immune response, which could be beneficial in certain conditions[8].

Dosage and Administration

The dosage of co-trimoxazole can vary depending on the condition being treated and the patient’s age and weight. It is typically taken orally (by mouth) in tablet form. Here are some examples of dosages used in clinical trials:

  • For tuberculosis: 960 mg once daily[1].
  • For melioidosis: Treatment for 12 or 20 weeks[2].
  • For pneumocystis pneumonia in HIV patients: Trimethoprim 15-20 mg/kg/day and sulfamethoxazole 75-100 mg/kg/day for 21 days[3].
  • For severe COVID-19 (in a clinical trial): 960 mg three times daily for 7 days[9].

It’s important to note that these dosages are from clinical trials and may not represent standard treatment. Always follow your doctor’s instructions for taking co-trimoxazole.

Potential Side Effects

Like all medications, co-trimoxazole can cause side effects. Some potential side effects include:

  • Rash or itching
  • Nausea or vomiting
  • Diarrhea
  • Headache
  • Dizziness
  • Unusual bruising or bleeding
  • Yellowing of the skin or eyes
  • Joint or muscle pain

In rare cases, more serious side effects can occur, such as severe skin reactions or blood disorders. If you experience any unusual symptoms while taking co-trimoxazole, contact your healthcare provider immediately[9].

Ongoing Research

Co-trimoxazole is being studied for various potential uses beyond its current applications. Some areas of ongoing research include:

  • COVID-19: Researchers are investigating whether high-dose co-trimoxazole could help treat severe COVID-19 by reducing inflammation and preventing complications[9].
  • Prevention of Spontaneous Bacterial Peritonitis: A study is looking at whether daily co-trimoxazole can prevent this type of infection in people with liver cirrhosis[7].
  • Comparison with Other Antibiotics: Researchers are comparing co-trimoxazole to other antibiotics like azithromycin for treating undifferentiated febrile illness in regions where diseases like typhoid fever are common[5].

These studies aim to expand our understanding of co-trimoxazole’s potential benefits and find new ways to use this well-established antibiotic.

Condition Trial Objective Co-Trimoxazole Use Key Outcomes Measured
Tuberculosis Evaluate pharmacokinetics of Co-Trimoxazole in TB patients 960 mg daily for 4-6 days Pharmacokinetic parameters, AUC/MIC ratio
Melioidosis Compare 12 vs 20 weeks of Co-Trimoxazole treatment 12 or 20 weeks of treatment 1-year non-relapse rate, clinical recurrence
Pneumocystis Pneumonia in HIV Evaluate Rezafungin + Co-Trimoxazole vs Co-Trimoxazole alone 7 days of Co-Trimoxazole Therapeutic failure, clinical improvement
Severe COVID-19 Assess Co-Trimoxazole’s effect on clinical outcomes High-dose Co-Trimoxazole for 7 days Length of hospital stay, mortality, oxygen requirements
Undifferentiated Febrile Illness Compare Co-Trimoxazole vs Azithromycin 7 days of treatment Fever clearance time, treatment failure
Neonatal Infections Identify bacterial pathogens and evaluate care package Used as treatment option Neonatal mortality rates, infection types
Spontaneous Bacterial Peritonitis Evaluate Co-Trimoxazole as primary prophylaxis 960 mg daily for 18 months Overall survival, SBP incidence, hospital admissions

FAQ

  • What is Co-Trimoxazole? Co-Trimoxazole is an antibiotic combination of trimethoprim and sulfamethoxazole. It is used to treat various bacterial infections and has been studied for its potential in preventing certain conditions.
  • In which medical conditions is Co-Trimoxazole being studied? Clinical trials are exploring Co-Trimoxazole's effectiveness in tuberculosis, melioidosis, pneumocystis pneumonia in HIV patients, severe COVID-19, undifferentiated febrile illness, neonatal infections, and spontaneous bacterial peritonitis in cirrhosis patients.
  • How is Co-Trimoxazole being used in COVID-19 trials? Some trials are investigating high-dose Co-Trimoxazole as a potential treatment for severe COVID-19 patients, studying its effects on hospital stay duration, oxygen requirements, and mortality rates compared to standard treatment.
  • What are the potential benefits of using Co-Trimoxazole for spontaneous bacterial peritonitis prevention? A clinical trial is evaluating Co-Trimoxazole as primary prophylaxis for spontaneous bacterial peritonitis in cirrhosis patients, aiming to improve overall survival and reduce the incidence of infections and related complications.
  • Are there any studies comparing Co-Trimoxazole to other antibiotics? Yes, one trial is comparing Co-Trimoxazole to Azithromycin for the treatment of undifferentiated febrile illness in Nepal to determine which antibiotic is more effective as empirical treatment.

Ongoing Clinical Trials on Co-Trimoxazole

  • Study on the Effect of Rifampicin and Drug Combination for Patients with Staphylococcus aureus Bacteremia

    Recruiting

    3 1 1 1
    Investigated drugs:
    France Germany The Netherlands Sweden

  • Study for Adults with Very High-Risk T-Cell Acute Lymphoblastic Leukemia Using Daratumumab and a Drug Combination

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study on the Effectiveness of Co-Trimoxazole for Treating Ventilator-Associated Pneumonia in ICU Patients Compared to a Drug Combination

    Not recruiting

    3 1 1 1
    Investigated drugs:
    France

Glossary

  • Co-Trimoxazole: An antibiotic combination of trimethoprim and sulfamethoxazole used to treat various bacterial infections.
  • Melioidosis: A potentially life-threatening infection caused by the bacterium Burkholderia pseudomallei, primarily found in tropical regions.
  • Pneumocystis Pneumonia (PCP): A type of pneumonia caused by the fungus Pneumocystis jirovecii, which commonly affects people with weakened immune systems, such as those with HIV/AIDS.
  • Spontaneous Bacterial Peritonitis (SBP): An infection of the peritoneal fluid in the abdominal cavity, often occurring in patients with advanced liver disease and cirrhosis.
  • Undifferentiated Febrile Illness: A fever without a clear cause or specific symptoms, which can be challenging to diagnose and treat.
  • Cytokine Storm Syndrome (CSS): An excessive immune response characterized by the release of large amounts of inflammatory molecules called cytokines, which can lead to severe tissue damage and organ failure.
  • MELD Score: Model for End-Stage Liver Disease score, used to assess the severity of chronic liver disease and prioritize patients for liver transplantation.
  • Transjugular Intrahepatic Portosystemic Shunt (TIPS): A medical procedure to create a new pathway between the portal vein and hepatic vein in the liver, used to treat portal hypertension and its complications in cirrhosis patients.

References

  1. https://clinicaltrials.gov/study/NCT01832987
  2. https://clinicaltrials.gov/study/NCT01420341
  3. https://clinicaltrials.gov/study/NCT05835479
  4. https://clinicaltrials.gov/study/NCT01757236
  5. https://clinicaltrials.gov/study/NCT02773407
  6. https://clinicaltrials.gov/study/NCT00198627
  7. https://clinicaltrials.gov/study/NCT04395365
  8. https://clinicaltrials.gov/study/NCT04470531
  9. https://clinicaltrials.gov/study/NCT04884490